December 27, 2022 at 9:52 pm

PRISM Electric Vehicle Stocks Fall Nearly 6% As EV Market Suffers

The PRISM Electric Vehicle Index fell 5.7% for the day, the biggest slip of all the PRISM Indexes. The EV market has been suffering lately, with big names reaching all-time lows. Rivian Automotive (RIVN) fell 7.3%, Lucid Group (LCID) fell 7% and ChargePoint Holdings (CHPT) fell 3.5%, to new lows. Not to mention, TSLA has… [Read More]
December 23, 2022 at 10:36 pm

OncoCyte Corporation (OCX) Shoots Up 29% A Week After Strategy Shift

OncoCyte (OCX), a medical diagnostics company, shot up 29% for the day. There’s no new press releases today, but the gains come shortly after several significant changes to the company. Seven days ago, OCX announced that the company was cutting 40% of their staff, and a new shift in corporate strategy. OncoCyte entered into a… [Read More]
December 22, 2022 at 9:23 pm

HTG Molecular Diagnostics (HTGM) Falls 28% As Company Announces Public Offering

HTG Molecular Diagnostics (HTGM) fell 28% for the day, shortly after announcing that they priced a $10 million public offering. “Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase 1,290,322 shares of common stock, at a combined public offering price of $7.75 per share (or pre-funded… [Read More]
December 22, 2022 at 12:01 pm

Lexaria Oral Nicotine Study Begins Dosing

Lexaria Bioscience, (Nasdaq: LEXX) has begun dosing subjects in an oral nicotine study that will compare DehydraTECH-nicotine pouch performance to existing leading brands ON!, manufactured by Altria, and Zyn, manufactured by Swedish Match. Highlights Lexaria’s study is a 36-person human pharmacokinetic randomized, double blinded, cross-over study conducted in current cigarette smokers. Each volunteer will visit… [Read More]
December 21, 2022 at 8:18 pm

Bionik Eyes $4.9 Billion Global Neurorehabilitation Devices Market with New Strategic Direction

Robotics and neurological recovery solutions company Bionik Laboratories (OTCPINK: BKNL), has unveiled a new strategic approach to rehabilitating stroke survivors and others with functional and mobility challenges while delivering long-term value for investors. Every 40 seconds, someone in the United States has a stroke, and it is a leading cause of serious long-term disability. Rehabilitation therapy… [Read More]
December 21, 2022 at 3:48 pm

Acumen Pharmaceuticals: Clinical-Stage Alzheimer’s Disease Treatment on FDA Fast Track

Clinical-stage biopharmaceutical company, Acumen Pharmaceuticals (Nasdaq: ABOS), continues making strides as it works towards developing a treatment for Alzheimer’s disease. The company’s therapeutic is the first clinical-stage monoclonal antibody designed to selectively target toxic soluble amyloid beta oligomers. In October 2022, Acumen received Fast Track designation from the FDA for ACU193, underscoring its clinical potential… [Read More]
December 20, 2022 at 11:36 pm

VolitionRx Limited (VNRX) Soars 15% on Positive Coverage From EF Hutton

VolitionRx Limited (VNRX), an epigenetics company, soared 15% plus another 5% in after-hours today. The gains largely come from EF Hutton initiating coverage on VNRX with a buy rating and a price target of $6. Currently, VolitionRx is sitting at under $3, giving VNRX plenty of room to grow. VolitionRx is also approaching their 52-week… [Read More]
December 19, 2022 at 8:36 pm

HTG Molecular Diagnostics (HTGM) Skyrockets 49%

HTG Molecular Diagnostics (HTGM) , a medical diagnostics company, jumped up 49% today, leading all stocks tracked by Prism MarketView. There is no news explaining the leap in share value, but it could be explained by a short squeeze. HTGM was listed as a short squeeze stock to watch, which may justify the pop. The… [Read More]
December 15, 2022 at 12:45 pm

Soligenix Submits New Drug Application to FDA

Soligenix, Inc., (Nasdaq: SNGX), a late-stage biopharmaceutical company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for HyBryte™, a treatment for cutaneous T-cell lymphoma (CTCL).  Watch the video interview.  Soligenix estimates the potential worldwide market for HyBryte™ (synthetic hypericin) to be in excess of $250 million for the treatment… [Read More]
December 14, 2022 at 9:46 pm

Wave Life Sciences (WVE) Soars Another 26% After Announcing Collaboration With GSK

Wave Life Sciences (WVE), rose another 26%, following yesterday’s 33% gain. The rise in value follows a lucrative collaboration with GSK. Wave receives upfront payments of $170 million in cash and equity, and is also eligible to receive milestone payments and royalties. The collaboration brings together Wave’s PRISM oligonucleotide platform and GSK’s expertise in genetics… [Read More]
December 14, 2022 at 12:03 pm

Quoin Pharmaceuticals Doses First Patient in Rare Disease Trial

Quoin Pharmaceuticals (Nasdaq:QNRX), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases has dosed the first patient in a clinical trial evaluating a treatment for Netherton Syndrome. The company has announced it will initiate a second study assessing its QRX003 topical lotion in Netherton patients who are currently receiving off-label treatment including… [Read More]